# Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

> **NCT04408755** · PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 184 (actual)

## Conditions studied

- Agitation in Patients With Dementia of the Alzheimer's Type

## Interventions

- **DRUG:** AVP-786
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04408755
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-13
- **Primary completion:** 2024-06-27
- **Final completion:** 2024-06-27
- **Target enrollment:** 184 (ACTUAL)
- **Why stopped:** The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04408755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04408755, "Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04408755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*